A new study has found that an experimental drug may delay the onset of Alzheimer’s-related dementia in people who are almost ...

Nicotine, an addictive stimulant found in the tobacco plant, can increase the release of dopamine and other neurotransmitters ...

Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio ...

A stroke drug called GAI-17 protected mouse brains even six hours after damage began—and may one day help fight Alzheimer’s ...

US Food and Drug Administration Commissioner Marty Makary signaled Thursday that he is open to revising strict warning labels ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompson—the R&D combo that has led Acadia ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

A new drug could one day revolutionize how stroke patients are treated by preventing further damage to the brain. Each year, some 795,000 people in the United States experience a stroke, the CDC ...